Cargando…

The ‘GA²LEN Sinusitis Cohort’: an introduction

Detalles Bibliográficos
Autores principales:	Vandeplas, Griet, Khan, Asif, Huynh, Thi Minh Thao, Tomassen, Peter, van Zele, Thibaut, Cardell, Lars-Olaf, Arebro, Julia, Olze, Heidi, Foerster, Ulrike, Kowalski, Marek Leszek, Olszewska-Ziąber, Agnieszka, Fokkens, Wytske, van Drunen, Cornelis, Mullol, Joaquim, Hellings, Peter, Hox, Valérie, Toskala, Elina, Scadding, Glenis, Lund, Valerie, Bachert, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4493526/ http://dx.doi.org/10.1186/2045-7022-5-S4-O1

Ejemplares similares

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Diagnostic tools in Rhinology EAACI position paper
por: Scadding, Glenis, et al.
Publicado: (2011)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Acute and chronic rhinosinusitis and allergic rhinitis in relation to comorbidity, ethnicity and environment
por: Hoffmans, Ruth, et al.
Publicado: (2018)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

A EUFOREA comment on a lost comorbidity of asthma
por: Conti, Diego M., et al.
Publicado: (2023)

Quality of life and use of medication in chronic allergic and non-allergic rhinitis patients
por: Segboer, Christine, et al.
Publicado: (2013)

Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
por: Van Broeck, Dorien, et al.
Publicado: (2023)

New insights into the pathogenesis of non-allergic rhinitis
por: Segboer, Christine, et al.
Publicado: (2015)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

Capsaicin for Rhinitis
por: Fokkens, Wytske, et al.
Publicado: (2016)

Multi-morbidities of allergic rhinitis in adults: European Academy of Allergy and Clinical Immunology Task Force Report
por: Cingi, C., et al.
Publicado: (2017)

Acute and chronic rhinosinusitis and allergic rhinitis in relation to environment, comorbidity and ethnicity
por: Hoffmans, Ruth, et al.
Publicado: (2015)

Early growth response protein 1 and dual specificity protein phosphatase 1 are involved in down-regulation of allergic responses
por: Golebski, Kornel, et al.
Publicado: (2013)

Endotyping of non-allergic, allergic and mixed rhinitis patients using a broad panel of biomarkers in nasal secretions
por: Segboer, Christine L., et al.
Publicado: (2018)

Activation of Activin receptor-like kinases curbs mucosal inflammation and proliferation in chronic rhinosinusitis with nasal polyps
por: Tengroth, Lotta, et al.
Publicado: (2018)

Corrigendum on: White paper on European patient needs and suggestions on chronic type 2 inflammation of airways and skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA
por: De Prins, Louise, et al.
Publicado: (2022)

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey
por: Price, David, et al.
Publicado: (2015)

Characterisation of interleukin-10 expression on different vascular structures in allergic nasal mucosa
por: Muller, Barbara, et al.
Publicado: (2014)

Breaking nasal epithelial cell tolerance lipopolysaccharide exposure by CD16 mediated co-stimulation with human serum immunoglobulin G
por: Golebski, Korneliusz, et al.
Publicado: (2015)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

Role of Innate Immunity in the Pathogenesis of Chronic Rhinosinusitis: Progress and New Avenues
por: van Drunen, Cornelis M., et al.
Publicado: (2012)

Editorial: Insights in rhinology: 2021/22
por: Smith, Peter Kenneth, et al.
Publicado: (2023)

Specific Induction of TSLP by the Viral RNA Analogue Poly(I:C) in Primary Epithelial Cells Derived from Nasal Polyps
por: Golebski, Korneliusz, et al.
Publicado: (2016)

dsRNA-induced changes in gene expression profiles of primary nasal and bronchial epithelial cells from patients with asthma, rhinitis and controls
por: Wagener, Ariane H, et al.
Publicado: (2014)

The Impact of Allergic Rhinitis and Asthma on Human Nasal and Bronchial Epithelial Gene Expression
por: Wagener, Ariane H., et al.
Publicado: (2013)

Expression profiling of nasal polyp epithelial cells identifies two distinct phenotypes and suggests a role for neurogenic inflammation
por: Cornet, Marjolein, et al.
Publicado: (2015)

Allergens, germs and asthma
por: Scadding, Glenis Kathleen
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2d53s0v0ddl90m0uj4ec0t1dqf